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Abstract — Microarray technology is expanding rapidly providing an extensive as 
well as promising source of data for better addressing complex questions involving 
biological processes. The ever increasing number and publicly available gene 
expression studies of human and other organisms provide strong motivation to carry 
out cross-study analyses. Besides, microarray technology provides several platforms 
to investigators that include arrays from commercial vendors like Affymetrix
®
 (Santa 
Clara, CA, USA), Agilent
®
 (Palo Alto, CA, USA), and other proprietorial arrays of 
various laboratories. Integration of multiple studies that are based on the same 
technological platform, or, combining data from different array platforms carries the 
potential towards higher accuracy, consistency and robust information mining. The 
integrated result often allows constructing a more complete and broader picture.  
In this work, we highlight as well as exemplify two frameworks of microarray data 
integration approaches that are in practice. This follows a discussion on the important 
issues that may influence any microarray data integration attempt. The review, in 
general, intends to serve as a starting point for those interested in exploring this area 
of microarray study, while realizing the pertinent issues underneath.     
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I. INTRODUCTION 
HE methods to measure gene expression were 
revolutionized by Kary Banks Mullis’s invention of the in 
vitro technique, polymerase chain reaction or PCR [1, 2] in 
1985 that awarded him Nobel prize for Chemistry in 1993. 
While application of PCR-approaches could detect the 
expression of one gene within one reaction or to a maximum 
of a few genes in optimised state, high-throughput analysis of 
higher number of genes was time consuming requiring a lot of 
technical and personal power. In 1995, two seminal 
investigations, Schena et al. [3] and Smith et al. [4], led by 
Patric O. Brown of the Howard Hughes Medical Institute, 
ushered in the era of gene-expression microarray analysis and 
revolutionized the field of molecular biology. The technique 
of microarrays, which started off with simultaneous gene 
expression analysis of 45 genes within one experiment, now 
provides technological and conceptual advancement through 
its high throughput capability of simultaneously interrogating 
the RNA expression of the whole genomes. 
In the relatively few years since its inception, microarray 
technology has improved dramatically, and becomes a widely 
used tool for studying global gene expression. Currently, it 
provides several platforms to researchers to carry out their 
investigations. In addition to arrays from commercial vendors 
like Affymetrix
®
 (Santa Clara, CA), Agilent
®
 (Palo Alto, CA), 
there are also proprietorial arrays used by various laboratories. 
Overall, microarrays have gained increasing use and 
acceptance to address a myriad of complex biological 
questions involving genetic and cellular processes. The 
increasing acceptance of microarrays is clearly demonstrated 
by the increasing number of citations appearing yearly in 
published literature. The researchers are particularly 
overwhelmed by the microarray-based methods as it confers 
the freedom to conduct large-scale gene expression profiling 
measurements giving rise to the resultant wealth of potentially 
valuable information within a very short span of time.   
With the increase of the collection of microarray data 
especially in MIAME [5]-compliance public repositories such 
as ArrayExpress
i
 [6], GEO
ii
 [7], CIBEX
iii
 [8], a growing 
number of investigators are looking at meaningful extraction 
of information by integration of various microarray 
experiments. As microarray study tends to explore specific 
areas of biological function, integration of data from multiple 
microarray experiments is considered to allow construction of 
a more complete as well as a broader biological picture. 
Integrated microarray data is potentially beneficial in several 
other ways including that it can compensate for the possible 
errors of individual experiments, amplify the sample-size, and 
can potentially lead to higher accuracy, consistency and robust 
information mining.  
Integration of microarray studies can include integration of 
studies that are based on the same technological platform. 
 
 
i http://www.ebi.ac.uk/arrayexpress 
ii http://www.ncbi.nlm.nih.gov/geo/ 
iii http://cibex.nig.ac.jp/index.jsp 
Researchers around the world also combine data from 
different array platforms based on their needs. However, 
integration of microarray data remains to be a challenging 
problem as data from different investigations do not become 
readily comparable due to factors that can be attributed to 
biological and technical causes associated with the generation 
of these data [9, 10]. Nevertheless, with the accumulating 
amount of important microarray data generated from various 
microarray experiments, many investigators have taken up the 
challenging task of meaningful integration of microarray data 
as well as of overcoming the barriers of microarray platform-
dependency in order to improve our understanding of 
biological processes, medical conditions, and diseases. In this 
paper, we highlight as well as exemplify two frameworks of 
microarray data integration. Besides, we have also listed the 
important issues that can influence any attempt of microarray 
data integration. Overall, this review is expected to serve as a 
starting point for those interested in exploring the area of 
microarray data integration. The article is also likely to be a 
‘one-stop shop’ to the readers enabling them to realize and be 
aware of a range of possible underlying issues in the 
microarray data integration-pipeline. 
  
II. MICROARRAY DATA INTEGRATION 
Microarray technology has become an indispensable tool 
for monitoring genome wide expression levels of genes in a 
given organism. From the Patric Brown’s lab, the technology 
has evolved representing both a technological and a 
conceptual advance of the field, and has expanded worldwide, 
where many laboratories are now making their own arrays, in 
addition to the availability of various commercial vendors. 
With the increasing number and availability of gene 
expression studies of various organisms, there has been a 
pressing need to develop approaches for integrating results 
across multiple studies.    
In a cross-study analysis, the data, relevant results and 
statistics of several studies are combined. There are different 
practical advantages in such studies. Cross-study analysis has 
the potential to strengthen and extend the results gathered 
from the individual studies. This can turn an investigation 
towards higher accuracy and consistency, and thus, help in 
robust information mining. Moreover, output of such a study 
can provide a broader picture of gene-expression as the final 
‘integrated’-result emerges based on a set of individual 
studies. Cross-study analysis can also compensate for the 
possible data-errors in individual studies. The cost of such a 
study can be kept low by using the existing studies, as 
otherwise the setting up of each microarray investigation is not 
inexpensive. However, while attempting to carry out 
integration of microarray studies, there are much higher 
challenges and difficulties as genetic expressions of different 
studies are neither readily comparable nor can directly be 
combined.  
There are several approaches to cross-study analysis, and 
they somewhat broadly fall into two categories – A. studies 
where integration occurs at the interpretative level, B. studies 
T 
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where integration takes place with rescaling of the expression 
values. 
 
A. Integration at the interpretative level 
Meta-analysis is emerging as a standard way for the 
comparison of microarray studies at interpretative level. It 
involves comprehensive reanalysis of the primary data by 
merging data from multiple studies. Certain general reviews 
on meta-analysis include Hedges & Olkin [11], Cook et al. 
[12], Normand [13], Ghosh et al. [14] and Moreau et al. [15]. 
As broadly defined by Normand [13], meta-analysis is the 
quantitative review and synthesis of the results of related but 
independent studies. Despite having certain demerits of 
merged primary dataset as reviewed by Larsson et al. [16], the 
method is becoming useful in microarray studies with the 
expansion of the sheer volume of microarray data. The success 
of meta-analysis is dependent on the quality of the underlying 
data. When accuracy of one or more concerned microarray 
platforms is questionable, the outcome may become 
influenced. Nevertheless, browsing through the various 
studies, where the observation on accuracy, reliability and 
reproducibility of microarray platforms clearly ranges from 
relatively discouraging [17, 18] through cautiously optimistic 
[9, 19] to impressive [20, 21], the overall assessment of the 
usefulness of meta-analysis of similar microarray studies is 
cautious optimism. Moreover, the major sources that 
contribute to the discordance in this regard are mainly – 
random noise, biological and experimental variations in the 
samples being analysed, and the variation due to the technical 
methodology used in the platforms. It is possible to overcome 
the discordance to a greater extent with judicious and robust 
application of relevant statistical methods, standard reporting 
methods, as well as careful application of meta-analysis 
techniques.   
The core objectives of meta-analysis are to increase 
efficiency in detecting an overall treatment effect, to estimate 
degree of benefit associated with a particular study, and to 
assess the amount of variability between studies etc. In the 
recent past, several statistical methods aiming at detecting 
differentially expressed genes among multiple conditions have 
been proposed in individual experiments [22, 23, 24, 25]. Pan 
[26] has published a comparative review on these statistical 
methods in replicated microarray experiments. However, most 
standard meta-analysis methods cannot be applied directly to 
microarray experiments as microarray technology is unique 
with its slew of issues, including its diverse experimental 
platforms, complicated data structures, presence of duplicate 
spots as well as often having a large number of genes tested 
for differential expression.   
In 1925, a simple application of meta-analysis was 
implemented as Fisher’s Inverse
2 test [27]. The method 
computes a combined statistic from the P-values obtained 
from the analysis of the individual datasets, S = -2 log(Πi Pi). 
Here, S follows a Chi-square distribution with 2l degrees of 
freedom under the joint null-hypothesis. The approach does 
not require additional analysis, and is easy to use; however, it 
cannot estimate the average magnitude of differential 
expression in microarrays just by working with the p-values. 
The approach also remains highly dependent on the method 
used in the individual analysis.  
Meta-analysis based on the t-statistic was reviewed by 
Normand [13] in the context of biostatistical applications. 
Choi et al. [28] adopted the classic biostatistical meta-analysis 
framework for microarray analysis, and implemented their 
methods as a Bioconductor [29]-package, GeneMeta
iv
. The 
approach of Choi et al. [28] was a model-based systematic 
integration of microarray datasets, where a hierarchical 
modeling approach to assess intra- and inter-study variation 
was used. The method estimated an overall effect size as the 
measure of differential expression for each gene through 
parameter estimation and model fitting. The effect size was a 
t-like statistic, which was the summary statistic for each gene 
from each individual dataset, and was defined to be a 
standardized mean difference between cancer and normal 
samples in a microarray data set. Integration of data using this 
meta-analysis method promoted the discovery of small but 
consistent expression changes and increased the sensitivity 
and reliability of analysis. Later, Hong and Breitling [30] 
found that this t-based meta-analysis method greatly improved 
over the individual analysis, however it suffered from 
potentially large amount of false positives when P-values 
served as threshold.  
Based on the traditional effect size model [28], Hu et al. 
[31] proposed a model for implementing an efficient 
methodology for identifying genes that are differentially 
expressed between lung adenocarcinoma samples and normal 
samples by modeling the effect size and integrating 
information from two Affymetrix oligonucleotide studies. In 
this study, they presented a measure to quantify Affymetrix 
gene chip data quality for each gene in each study where the 
quality index measured the performance of each probeset in 
detecting its intended target. They extended the traditional 
effect size model by using the quality index as a weight for 
combining information from different Affymetrix chip types, 
and incorporating this weight into a random-effects meta-
analysis model.  
Rhodes et al. [32] proposed a statistical model for 
performing meta-analysis in their four prostate cancer 
microarray datasets, two of which were cDNA (also known as, 
spotted arrays) data and the remainder Affymetrix microarray 
data. The model was based on the statistical confidence 
measure rather than the expression levels, while avoiding 
direct comparisons of data sets and related cross-platform 
normalization issues. Each gene in each study was treated as 
an independent hypothesis, and significance was assigned 
based on random permutations. Then a meta-analysis model 
was implemented to assess the similarity of the findings 
between studies based on multiple inference statistical test for 
each possible combination of studies. This ultimately 
identified statistically reliable sets of over- and under-
expressed genes in prostate cancer. A cohort of genes were 
 
iv www.bioconductor.org/packages/bioc/html/GeneMeta.html 
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found to be consistently and significantly dysregulated in 
prostate cancer. The approach of Rhodes et al. is highly 
conservative because of the choice of null hypothesis; and 
therefore, the approach may not be recommendable. The data 
used by Rhodes et al. [32] were later used by Choi et al. [28], 
and they demonstrated that their method could lead to the 
discovery of small but consistent expression changes with 
increased sensitivity and reliability.  
A Bayesian mixture model transformation of microarray 
data was proposed by Parmigiani et al. [33]. The modeling 
framework was used for molecular classification, and it 
provided both a statistical definition of differential expression 
and a precise, experiment-independent, definition of a 
molecular profile. It also generated natural similarity measures 
for traditional clustering and gave probabilistic statements 
about the assignment of tumors to molecular profiles.  
The rank product is a non-parametric statistic, and was first 
proposed to detect differentially expressed genes in a single 
dataset [22]. To integrate multiple microarray studies from 
different platforms and/or different laboratories, a rank 
product meta-analysis algorithm was implemented as a 
Bioconductor package, RankProd [34]. The algorithm 
computed pairwise fold change (FC) with replicates for each 
gene between treatment and control in both directions, 
respectively. Then, it transformed FC into rank among all 
genes under study, searched for genes that were consistently 
top ranked across replicates, and finally generated a single 
significance measurement for each gene in the combined 
study. In this approach, converting FC into ranks increased 
robustness against noise and heterogeneity across studies.  
Grutzmann et al. [35] performed a meta-analysis of four 
independent studies that applied high-density arrays for 
expression profiling of pancreatic cancer. They used a 
consensus set of UniGene clusters measured in all four 
studies, and applied a random effect model described by 
Whitehead & Whitehead [36], whereby expected values of 
individual study effects were assumed to be normally 
distributed. With the random effect model, an unbiased 
estimator for the PDAC (Pancreatic ductal adenocarcinoma) 
effect across all studies was measured, and was used to 
measure joint differential expression of a gene across all 
studies. 
With three publically available breast cancer datasets 
having information on lymph node status, Garrett-Mayer et al. 
[37] compared the strength of evidence of gene–phenotype 
associations as well as combined effects across studies. For 
this, the three studies were first analyzed for reliability, and 
then, the comparability of results with regards to the genes 
associated with lymph node status was assessed. Instead of 
actually combining the data across studies, they mainly 
performed a comparative analysis making inferences based on 
the genes consistently measured in all studies, and finally 
estimated combined inferential statistics. Their proposed 
methods were implemented in the R [38]-library, MergeMaid
v
 
[39]. The novel addition in this work was the use of a 
 
v http://astor.som.jhmi.edu/MergeMaid/ 
reliability measure, which was extended to be applied for 
more than two studies. 
Meta-analyses methods are useful; however, as Eysenck 
[40] mentioned, they require careful selection of inclusion 
criteria for participating studies and sound statistical models to 
avoid misleading conclusions. To date, a broader comparison 
across various integration approaches is not available. 
However, Hong and Breitling [30] compared performance of 
three widely used methods - Fisher’s inverse Chi-square 
approach, t-like statistic of Choi et al. [28] and rank product 
method [22, 34], and found that the non-parametric rank-
product method outperformed in terms of sensitivity and 
specificity.     
In general, the overall framework used in all the above 
studies, where data integration occurs at the interpretative 
level can be outlined as shown in Fig. 1.  
 
 
Fig. 1 Outline to the stages of microarray data integration at 
interpretative level 
 
B. Integration with rescaling of the expression values  
Contrary to the meta-analysis approaches, where the results 
of the individual studies are combined at an interpretative 
level, there are published researches where microarray 
expression data from various studies are integrated after 
transforming the expression values to numerically comparable 
measures. This is attained by deriving the genetic expression 
values from the individual platforms, and then, applying 
specific data transformation and normalization methods. The 
derived data from the individual studies are subsequently 
combined, which enlarges the sample size. Any further 
analysis, as required, is carried out on the new merged dataset. 
The cross-referencing of the genes between the platforms is 
usually achieved using UniGene database [41].  
Ramaswamy et al. [42] reported rescaling of gene-
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expression values of a common set of genes. The set of the 
common genes were from five microarray datasets generated 
by individual labs on different microarray platforms. The 
rescaled common genes were combined to produce a larger set 
of data. From the combined dataset, a gene expression 
signature was identified, which distinguished primary from 
metastatic tumors.  
A standard normalization scheme can be used to combining 
cDNA and Affymetrix data. Hwang et al. [43] normalized the 
expression values of each gene across the samples for each 
platform so that the mean of each gene equals to zero and the 
standard deviation equals to unity, respectively. The 
normalized data were, then, combined to form a large dataset. 
Earlier, Cheadle et al. [44] proposed normalization and 
standardization of cDNA microarray intensity values within 
datasets using a Z-score transformation method. The method 
converted the raw intensity data from each experiment into 
log10, and then, Z-scores were calculated by the classical 
method, i.e., by subtracting the overall average gene intensity 
(within a single experiment) from the raw intensity data for 
each gene, and dividing that result by the standard deviation of 
all of the measured intensities. The application of this classical 
method in microarray normalization provided a way of 
standardizing data across a wide range of experiments, while 
allowing comparison of microarray data independent of the 
original hybridization intensities.  
Based on the distance weighted discrimination (DWD) 
method of Marron & Todd [45], Benito et al. [46] integrated 
cDNA data with Agilent oligonucleotide data. DWD, which 
was basically an improvement method for Support Vector 
Machines in HDLSS (High Dimension, Low Sample Size) 
contexts, was used as an approach for removing systematic 
bias effects and then, merging the different data sets.  
A gene-specific scaling factor was calculated in Bloom et 
al. [47], and was used to integrate microarray data from 
Affymetrix and cDNA platforms. Here, for each gene 
common to both platforms, expression levels for a reference 
RNA sample on the spotted arrays was averaged and 
compared to expression measured for the reference RNA 
sample on the appropriate Affymetrix GeneChip to calculate 
the scaling factor. This scaling factor was used to adjust the 
remaining data towards integrating the platforms.   
Shen et al. [48] used a two-stage Bayesian mixture 
modeling strategy based method proposed by Parmigiani et al. 
[33]. This model was to integrate multiple independent studies 
addressing similar questions while considering different 
platforms – Affymetrix and inkjet oligonucleotides. The 
mixture modeling approach reportedly unified disparate gene 
expression data based on a probability scale of differential 
expression, the poe-scale [33], and derived an inter-study 
validated 90-gene ‘meta-signature’ that predicted relapse-free 
survival in breast cancer patients. 
In addition to common data transformation and 
normalization procedures, Jiang et al. [49] added a distribution 
transformation (disTran) step in their study. The method 
transformed two microarray datasets belonging to two 
Affymetrix chip types so that the empirical distributions of 
two lung cancer datasets could become identical and be 
combined. The disTran method reportedly provided improved 
consistency in the expression patterns of the multiple datasets.  
Two data integration methods, namely quantile 
discretization (QD) and median rank scores (MRS) were used 
in Warnat et al. [50] for direct integration of raw microarray 
data from six publicly available cancer microarray gene 
expression studies conducted by means of cDNA and 
oligonucleotide microarrays. In this study, comparable 
measures of gene expression from the independent data sets of 
the varied microarray platforms were numerically derived 
such that the different microarray data adhere to a common 
numerical range. These derived data were then integrated, and 
used to build SVM (support vector machine) classifiers for 
cancer classification. Similar to disTran, the quantile 
normalization technique, i.e., MRS, and QD of Warnat et al. 
[50] were used to transform the microarray data from diverse 
platforms so that their empirical distributions are identical. 
The approaches (disTran, MRS and QD) can significantly 
improve the comparability of cross-platform microarray data. 
These methods work well for classification tasks, but can 
suffer from information reduction, limiting their applicabilities 
other than classification.       
Stafford & Brun [51] presented a calibration process for 
cross-laboratory and cross-platform microarray expression 
data. Using Agilent and Affymetrix expression platforms, they 
employed precision and sensitivity measurements along with 
biological interpretation for better selection of genes with 
respect to a particular outcome. Precision and sensitivity 
measurements were useful in finding the minimal detectable 
fold-change and raw performance values for a microarray 
platform. Gene Ontology and pathway analyses were 
considered in the study as a valuable way of examining and 
comparing the actual biological interpretation.  
Xu et al. [52] used four independent breast cancer datasets, 
and identified a structured prognostic signature consisting of 
112 genes organized into 80 pair-wise expression 
comparisons. They extended a previously proposed method 
[53], validated on a prostate cancer study, to predict distant 
metastases in breast cancer. The method of integration was 
based on the ranks of the expression values within each 
sample. Since the ranks of the features were invariant to all 
types of within-array preprocessing, there was no need to 
prepare the data for integration, in particular there was no need 
for data normalization. 
XPN [54] is another method that deals with the problem of 
cross-study normalization: how to combine microarray 
datasets in order to produce a single, unified dataset to which 
standard statistical procedures can be applied. The method was 
based on a block linear model, and used three existing breast 
cancer datasets from Agilent oligonucleotide platform and 
Affymetrix GeneChip. The model assumed that the samples of 
each available study fell roughly into one of the statistically 
homogenous sample groups identified, and that each group 
was defined by an associated gene profile that was constant 
within each of the estimated gene groups. The proposed 
method applied sample standardization and gene median 
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centering before combining the data from the studies. To 
identify blocks (or, clusters) in the data, k-means clustering 
was applied independently to genes and samples of the 
combined data. Each gene expression value subsequently 
became a scaled and shifted block mean plus noise. XPN was 
reportedly preserved biological information according to ER 
(error rate) prediction error rates while removing systematic 
differences between platforms.  
NLT or Normalized Linear Transform [55] is a method in 
which the samples of two microarray platform were linearly 
mapped such that the numerical range of the expression values 
of each gene became identical. The mapped data were, then, 
combined and normalized across samples to zero mean and 
unity standard deviation. Apparently, the approach avoids 
information reduction as it preserves the relative ranking order 
of the expression values for each gene.     
The methods highlighted above pose important examples of 
integration of microarray datasets with rescaling of the gene 
expression values. Each of the approaches is unique; however, 
their overall stages follow a general framework as outlined in 
Fig. 2. A user should also be aware that all the methods do not 
support small sample size. In an attempt to extend a study of 
Sarmah et al. [56] where the authors used 7-Affymetrix and 7-
cDNA samples, only DWD method [46], out of DWD, poe 
[33, 48] and XPN [54], could successfully integrate the 
results. It is also overall found during the current study that an 
elaborate comparative analysis on the performance of the 
individual microarray data integration approaches is still 
awaited.    
 
  
 
Fig. 2 Outline to the stages of microarray data integration with re-
scaling of expression values 
III. ISSUES WITH INTEGRATION OF MICROARRAY DATA 
The microarray integration studies are valid only if the basic 
underlying issues are considered as well as addressed with 
proper attention during the conduct of these studies. We are 
discussing here a delineation of issues that are important to be 
reminded of while achieving throughput from such integration 
efforts.   
 
A. Diversified platforms and noise 
This is of fundamental knowledge that there is a range of 
available microarray platforms; besides, various laboratories 
also make their own arrays to carry out investigations. Stears 
et al. [57] provides a list of commercial microarray vendors. 
With the increasing number and accessibility of gene 
expression studies of various organisms, each available 
platform of this technology serves as a genomic readout along 
with unique characteristics that offer advantages and/or 
disadvantages in a given context. Further, due to the nature of 
the technology, noise is an inescapable phenomenon, which 
can infiltrate at any stage during the process. Draghici [58] 
compiles a list of major sources of noise. Basic understanding 
about the platforms, the associated noise and their effects can 
prove to be useful during any type of microarray investigation 
including data integration.   
 
B. Preliminary data treatment 
There is always some cleaning of the raw, individual 
datasets before proceeding to the core of the analysis. The 
cleaning usually extracts or enhances meaningful data 
characteristics. The goal of cleaning the data, with or without 
normalization, should be to retain the most accurate data 
rather than finding the most significant result. The attempt to 
find the latter can come any time after the end of this process.      
 
C. The excluded genes – are they important ? 
As commonly observed in the direct integration approaches 
where merging of microarray data is done with the rescaling 
of the gene expression measures, the approaches consider a 
consensus set of genes from the concerned studies. That way, 
some genes are excluded from the analysis pipeline right after 
the preliminary stage. Selecting and reassessing the excluded 
genes at some stage during the process of study may be 
important to ascertain that potentially significant genes have 
not been left out from the analysis. 
 
D. Hunt for the best gene-selection method !  
There is no gold-standard of methods which is completely 
fool-proof, and can efficiently select only the important genes 
from microarray studies. Therefore, a certain probability of 
error in such selection always remains as the strict methods 
would tend to leave out certain significant genes while others 
would leave room for the unimportant genes to appear in the 
experiment diluting the successive analysis stages. An 
example of it is to keep a high (strict) or a relaxed threshold 
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while using gene selection methods such as fold change (a 
method where an arbitrary ratio relating the expression level 
of a gene under control and experimental conditions is 
considered significant) or unusual ratios (method of selecting 
genes certain standard deviations away from the mean log-
ratio). A high threshold would find a small number of genes as 
important, whereas a relaxed threshold would select a high 
number of genes. Thus, it is important to take extra care in the 
selection of genes so that an optimum number of important 
genes can be retrieved.  
         
E. Microarray data repositories      
Various microarray data repositories have been established 
worldwide to share microarray data. With every passing year, 
there is increase of repositories. However, the reliability of the 
data quality in each of these repositories is not secured – some 
repositories are undoubtedly of high quality, but it is doubtful 
whether the same applies to all available repositories. This 
makes it important that an investigator verifies her/his data 
quality beforehand so that once the data are integrated, the 
combined output gives accurate as well as meaningful results. 
Further, open source software packages, such as Microarray 
Retriever or MaRe [59], WebArrayDB [60], and A-MADMAN 
[61], have also started coming along that facilitate searching 
and data retrieval from public microarray repositories.  
 
F. Considering appropriate data 
Many times, the data in public repositories tend to act as 
convenience samples for the investigators. This makes the data 
to be combined inappropriate for the question(s) being asked. 
For example, while studying causes of a disease, if the data 
come from people already affected by that disease, it may not 
make sense because the resultant study may only reveal effects 
of the disease. Again, while studying a particular disease, it 
may not be worthwhile to use data from a different disease 
type or from healthy cases, unless there are reasons behind 
doing so. Thus, it is critical that selection of data must be 
carefully considered, and the selected data are appropriate for 
the question(s) being asked.   
 
G. Data analysis 
This is essential to bear in mind that publically available 
datasets of any two microarray investigations could have 
passed through different levels of data transformations 
including background correction, probeset summarization and 
normalization. All these lead to several combinations of 
possibilities, and high concordance in the outputs of these 
transformations is rarely found. In the MAQC project [62], 
effects of summarization and normalization strategies have 
been evaluated. Further, Gagarin et al. [63] reports 30% 
concordance in the differentially expressed gene lists while 
applying two different summarization methods in the same 
dataset.     
       
H. Gene nomenclature 
Any two microarray studies can be impossible to compare 
as their results may be reported in different gene 
nomenclatures. Results of microarray investigations can be 
reported in many ways, such as using Genbank [64], Entrez 
Gene [65], EMBL [66], Unigene [67], RefSeq [68], OMIM [69] 
and Affymetrix gene identifiers. Without using translation 
tools, like DAVID [70], GoMiner [71], RESOURCERER [72], 
L2L [73] and LOLA [74], it is very difficult to compare 
microarray studies.    
 
I. Probe contents 
The probe contents of different microarray platforms are 
varied. The probes for cDNA platform are often obtained from 
cDNA libraries. The cDNA libraries are common, but there 
are concerns about annotation, clone identity, and probe 
performance [75]. Commercially available oligonucleotide 
libraries are gaining acceptance as the annotation and identity 
of oligonucleotides in these libraries are reliable, and the 
hybridization characteristics of oligonucleotides are generally 
good [76].  
J. Use of different splice-variants as probes: 
Various tools, as mentioned earlier, help in translation 
between different nomenclatures. However, different 
microarray platforms use different splice forms of the 
transcripts. Ideally, we must know all the relevant splice-
variants of the transcripts along with quantification of the 
sensitivity and specificity of the probes for nomenclature 
translation between different platforms. However, in practical, 
it is so far not yet completely achievable. MAQC project [62] 
shows that it could only cross-reference 12,091 transcripts 
between all of the major platforms, although some array 
platforms interrogate over 54,000 transcripts.  
 
K. Time of sample collection  
It is important to consider the time of collection of the 
tissue-sample. For studying a disease or treatment, the time 
when the tissue sample has been collected can alter the results 
significantly.    
 
L. Biological questions  
In normal circumstances, the common metaphor, ‘compare 
apple to apple’ holds relevance in microarray data integration 
in the sense that it is only reasonable to integrate microarray 
experiments that aim to address the same or similar biological 
questions.     
 
M. Variations in samples 
Variation in samples used may result in the variation in 
genes identified by different studies. Many times, similar 
investigations use different cell lines, tissues or specimens. On 
the other hand, even slight variation in the experimental 
conditions may influence investigations on identical cell lines. 
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All these can be influential in any microarray data integration 
attempt.  
 
N. Organismal variation       
There are gene expression variations from individual to 
individual within any population. Pritchard et al. [77] provides 
an example of such population variance where despite 
identical experimental parameters, the same organs from 
isogenic mice show distinct and detectable variability in 
expression. This form of organismal variation can only be 
examined by multiple repeats at the organismal level (i.e., 
multiple mice for each biological group). Thus, RNA from 
different tumors, each subjected to a microarray analysis, 
provides more information than replicate arrays run on a 
single batch of RNA extracted from either a single tumor or 
pooled tumors.  
 
O. Time-series and steady state data       
The steady state and time-series experiments are different. 
In the former, a snapshot of the expression of genes in 
different samples is measured while a temporal process is 
measured in time-series expression experiments. Moreover, 
while steady state data from a sample population are assumed 
to be independent identically distributed, time-series data 
exhibit a strong autocorrelation between successive points. 
Any attempt to combine these two types of microarray 
experiments must, therefore, have reason(s) to do so.   
 
P. Biological factors 
While focusing on microarray data integration, it is 
necessary to bear in mind that the results of microarray 
experiments cannot be trusted entirely. This is a technology 
which, in most cases, works at the mRNA level, and therefore, 
remains distanced from many underlying mechanisms. For 
example, in most cases, the microarrays measure the amount 
of mRNA specific to a particular gene as it is based on the 
premise that the expression level of the gene is directly 
proportional to its amount of mRNA. But it is not always true 
that the amount of mRNA accurately reflects the amount of 
protein. And, even if it is assumed that it does, a protein may 
require post-translational modification(s) to become active and 
perform its role in a cell.    
         
Q. Software tools 
There are several software tools available for microarray 
data analysis. Information on various software tools is 
available from sources like SMD
vi
, Mark Fontenot's 
Microarray Software List
vii
 at Southern Methodist University, 
Texas and Dresen et al. [78]. A few of the available tools are 
most widely used and comprehensive open source systems, 
such as the statistical analysis tools written in R [38] through 
the Bioconductor project [29], the TM4 software system [79] 
 
vi SMD or, Stanford Micoarray Database (http://tinyurl.com/24skjy2) 
vii http://tinyurl.com/3xk83jn 
available from The Institute for Genomic Research (TIGR; 
Rockville, MD, USA), and BioArray Software Environment 
[80] developed at Lund University, Sweden 
(http://base.thep.lu.se). An useful review on microarray 
software tools is by Dudoit et al. [81]. Further, the open source 
web-applications, such as WebArrayDB [60], A-MADMAN 
[61], microarray retriever [59], are also available for retrieval 
and analysis of microarray data. Overall, there are several 
options available for a user to investigate microarray data. The 
downside of it, however, is that different software packages or 
tools may, at times, generate varying results for essentially the 
same analysis. 
 
IV. CONCLUSION 
Microarray technology has strongly emerged due to the fact 
that it can provide a rapid snapshot of gene expression pattern 
of a tissue. It also helps in our understanding of global 
networks of bio-molecular interactions. Scientific areas 
including diagnosis, drug development, functional genomics, 
and comparative genomics are stimulated with the 
development of this high throughput technique resulting in 
avalanche of data from innumerable number of experiments.  
With the emergence of microarray technology from the 
shadows of being ‘cautionary tale’ [82], the steps towards the 
growth in the area of microarray data integration have been 
initiated. The analysis carried out maintaining highest 
standards, use of sound study-design, application of robust 
statistical application as well as adoption of reporting 
standards can help in the maturity of this area, and to march 
towards unlocking the hidden treasures of biological 
knowledge.   
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